CN1537544A - Composition of medicine for lowering fat, and its prepn. method - Google Patents
Composition of medicine for lowering fat, and its prepn. method Download PDFInfo
- Publication number
- CN1537544A CN1537544A CNA031089712A CN03108971A CN1537544A CN 1537544 A CN1537544 A CN 1537544A CN A031089712 A CNA031089712 A CN A031089712A CN 03108971 A CN03108971 A CN 03108971A CN 1537544 A CN1537544 A CN 1537544A
- Authority
- CN
- China
- Prior art keywords
- radix
- lipid
- group
- fructus crataegi
- polygoni multiflori
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 39
- 238000000034 method Methods 0.000 title claims abstract description 6
- 239000000203 mixture Substances 0.000 title claims description 81
- 239000000463 material Substances 0.000 claims abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 28
- 150000002632 lipids Chemical class 0.000 claims description 26
- 239000000843 powder Substances 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 10
- 239000002994 raw material Substances 0.000 claims description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 6
- 239000012141 concentrate Substances 0.000 claims description 5
- 230000000881 depressing effect Effects 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 239000006228 supernatant Substances 0.000 claims description 5
- 229940126672 traditional medicines Drugs 0.000 claims description 5
- 239000000796 flavoring agent Substances 0.000 claims description 4
- 235000019634 flavors Nutrition 0.000 claims description 4
- 238000005453 pelletization Methods 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 3
- -1 filter Substances 0.000 claims description 2
- 239000000890 drug combination Substances 0.000 claims 1
- 201000005577 familial hyperlipidemia Diseases 0.000 abstract description 34
- 240000001341 Reynoutria japonica Species 0.000 abstract description 2
- 235000018167 Reynoutria japonica Nutrition 0.000 abstract description 2
- 241000213006 Angelica dahurica Species 0.000 abstract 1
- 241000219780 Pueraria Species 0.000 abstract 1
- 230000000055 hyoplipidemic effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 55
- 210000004369 blood Anatomy 0.000 description 34
- 239000008280 blood Substances 0.000 description 34
- 229940079593 drug Drugs 0.000 description 24
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 24
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 21
- 210000002966 serum Anatomy 0.000 description 19
- 230000009467 reduction Effects 0.000 description 18
- 241000283973 Oryctolagus cuniculus Species 0.000 description 16
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 14
- 238000000465 moulding Methods 0.000 description 13
- 210000002784 stomach Anatomy 0.000 description 13
- 241000272201 Columbiformes Species 0.000 description 10
- 108010023302 HDL Cholesterol Proteins 0.000 description 10
- 229960002297 fenofibrate Drugs 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 150000002338 glycosides Chemical class 0.000 description 8
- 201000001320 Atherosclerosis Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 108010028554 LDL Cholesterol Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 230000002262 irrigation Effects 0.000 description 6
- 238000003973 irrigation Methods 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 241000282894 Sus scrofa domesticus Species 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 229930182470 glycoside Natural products 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- 102000007330 LDL Lipoproteins Human genes 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 3
- 235000005687 corn oil Nutrition 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000012567 medical material Substances 0.000 description 3
- 230000001603 reducing effect Effects 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- DSLZJTNJHMUOTH-UNGPUTHSSA-N (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[2-[[(2S)-1-[[(2S)-1-amino-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]propanoyl]amino]-3-methylbutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoic acid Chemical group CC(C)C[C@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)C(=O)N[C@@H](C(C)C)C(N)=O DSLZJTNJHMUOTH-UNGPUTHSSA-N 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- HWGBHCRJGXAGEU-UHFFFAOYSA-N Methylthiouracil Chemical compound CC1=CC(=O)NC(=S)N1 HWGBHCRJGXAGEU-UHFFFAOYSA-N 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- 210000001715 carotid artery Anatomy 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000002481 ethanol extraction Methods 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- 229940058769 fenofibrate 30 mg Drugs 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 229960002545 methylthiouracil Drugs 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 235000013547 stew Nutrition 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- 241000049624 Alisma plantago-aquatica subsp. orientale Species 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 241000005787 Cistanche Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 240000007711 Peperomia pellucida Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 101000800134 Rattus norvegicus Thyroglobulin Proteins 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 210000000497 foam cell Anatomy 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000008604 lipoprotein metabolism Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229910052573 porcelain Inorganic materials 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A hypolipemic Chinese medicine for treating the hyperlipemia is prepared from 5 Chinese-medicinal materials including pueraria root, haw, fleece flower root, Chinese angelica root, etc. Its preparing process is also disclosed.
Description
Invention field
The present invention relates to a kind of lipid-lowering composition, is a kind of Chinese traditional medicines depressing lipid compositions specifically, the invention still further relates to the preparation technology of said composition.
Background technology
Hyperlipemia is divided into former and secondary two big classes clinically, is the consequence of lipid and lipoprotein metabolism disorder in the numerous disease.Therefore, research and treatment hyperlipemia have important relationship with the control numerous disease.Particularly hyperlipemia causes atherosclerosis, causes cordis and cerebral accident, and the state of an illness is dangerous, prognosis mala.At present, all there is bigger side effect in Chang Yong fat-reducing medicament clinically.And life-time service, the part medicine can be big because of gastrointestinal reaction, causes consequences such as fatsoluble vitamin malabsorption.In addition, because crowd's individual variation is bigger, to the curative effect and the also bigger different and difference of existence of reaction of medicine.And the treatment by Chinese herbs hyperlipemia has certain curative effect, is better than Western medicine aspect toxic and side effects, is fit to take for a long time, discloses a kind of capsule for descend of blood fat as CN1263772A, and it is made up of Fructus Crataegi, the Radix Polygoni Multiflori, Rhizoma Alismatis, Radix Bupleuri, Radix Salviae Miltiorrhizae, Pericarpium Citri Reticulatae, Semen Raphani, Radix Curcumae; Have that strengthening spleen, tonifying kidney is soothing the liver, promoting blood circulation to remove stagnancy blood stasis dispelling effect, treatment fatty liver, hyperlipemia total effective rate reach 85%; CN1364512A discloses a kind of defatting and poison expelling capsule, select Radix Et Rhizoma Rhei, the Radix Polygoni Multiflori, Semen Cassiae, Rhizoma Alismatis for use, through ethanol extraction, Fructus Gardeniae, Radix Bupleuri, Rhizoma Curcumae, Fructus Crataegi, Herba Artemisiae Scopariae water are carried, make capsule, it can treat and prevent hyperlipemia, blood fat reducing, elimination hemorheology obstacle, and instant effect, cure rate height and treatment cycle are short.
CN1156601A discloses a kind of lipid lowerers, it is to select Rhizoma Polygoni Cuspidati, Radix Curcumae, Pericarpium Citri, Folium Nelumbinis, Fructus Crataegi, Radix Astragali, Fructus Schisandrae Chinensis, Rhizoma Atractylodis Macrocephalae (parched), Fructus Ligustri Lucidi, Herba Cistanches, Herba Epimedii, Radix Et Rhizoma Rhei, Rhizoma Alismatis for use, mix and decoct, concentrate and make, have soothing liver and strengthening spleen, tonify Qi of the kidney, blood circulation invigorating efficacies, can reduce the content of cholesterol and triglyceride in the blood, increase hdl concentration, quicken the curative effect of lipid metabolism.However, the curative effect of above-mentioned these medicines is owing to lack complete testing data and the evaluation of objective concrete experimental data, so all remain further to be investigated.So still need at present according to the Chinese medicine theory, in conjunction with contemporary Chinese medicine research achievement, dialectical with debate disease and combine, select suitable drug matching to use, develop a kind of definite lipid reducing and regulating effect that both had, side effect and reacting phase are to less, be beneficial to for a long time again and take, while scalable human body body function and equilibrated novel purely natural Chinese medicine, this is to the treatment hyperlipemia, and prevention cardiovascular and cerebrovascular disease and senile pathological changes have significance.
With single medical material such as Fructus Crataegi, Radix Puerariae, Rhizoma Alismatis, fleece flower root for treating hyperlipemia, coronary heart disease and atherosclerosis report is arranged all.With these medicines serves as main form compound recipe to be used for the treatment of cardiovascular disease more common, from these medicines, can extract the effective site or the effective ingredient of the sick disease of treatment painstaking effort, as Fructus Crataegi ketone treatment angina pectoris, Fructus Pyri Pashiae extractum treatment hyperlipemia, Radix Puerariae flavone treatment angina pectoris, Radix Polygoni Multiflori extractum treatment hypercholesterolemia, injection treatment coronary heart disease, Radix Angelicae Sinensis injection treatment thromboangiitis, ferulic acid anticoagulant, Rhizoma Alismatis saponins for treating hyperlipemia.But up to now, do not find these several herbal medicines are combined the bibliographical information of more effectively treating hyperlipemia.
Summary of the invention
Purpose of the present invention just provides a kind of Chinese traditional medicines depressing lipid compositions of determined curative effect.
Another object of the present invention provides the preparation method of this Chinese medicine composition.
Chinese medicine composition of the present invention is made up of active component and/or pharmaceutically acceptable carrier, and wherein active component is made by following raw materials by weight percent:
Radix Puerariae 25-35%, Fructus Crataegi 25-35%, Rhizoma Alismatis 10-20%, Radix Polygoni Multiflori 10-15% and Radix Angelicae Sinensis 5-10%.
Preferred active component is to be made by following raw materials by weight percent:
Radix Puerariae 28-33%, Fructus Crataegi 28-33%, Rhizoma Alismatis 10-15%, Radix Polygoni Multiflori 11-14% and Radix Angelicae Sinensis 5-8%.
More preferably active component is to be made by following raw materials by weight percent:
Radix Puerariae 32%, Fructus Crataegi 32%, Rhizoma Alismatis 15%, Radix Polygoni Multiflori 13% and Radix Angelicae Sinensis 8%.
If Fructus Crataegi is selected Fructus Crataegi (parched) for use in above-mentioned raw materials, Radix Polygoni Multiflori is selected Radix Polygoni Multiflori Preparata for use, and curative effect is better.Fructus Crataegi (parched): according to appendix IID of 95 editions pharmacopeia (medicinal material processing general rule three. big gun is processed 1. and is fried) in fry method: get clean Fructus Crataegi and put in the heat pot, fry to complexion changed when dark, take out, cool, get final product with slow fire; Radix Polygoni Multiflori Preparata: according to appendix IID of 95 editions pharmacopeia (medicinal material processing general rule three. big gun is processed 7. and is stewed) stew method: get clean Radix Polygoni Multiflori pieces, mix thoroughly, put in the porcelain container with decoction of black soybean, airtight, stew when juice exhausts with steam heated, cool, taking-up, drying gets final product.
Lipid-lowering composition of the present invention is selected promoting digestion and removing stagnation, blood circulation promoting and blood stasis dispelling, strengthening spleen, tonifying kidney, clearing away heat-damp and promoting diuresis medicine prescription for use.Be monarch drug with Fructus Crataegi (parched), Radix Puerariae in the side, removing food stagnancy blood stasis removing, invigorating the spleen and regulating the stomach; Rhizoma Alismatis is a minister, assists monarch drug, makes its blood stasis dispelling blood and does not hinder fresh blood, and dissipating depression of QI gas and do not hinder healthy energy makes heresy that outlet be arranged, jointly at primary symptom; Assistant is with Radix Polygoni Multiflori Preparata, merit in the replenishing essence the kidney invigorating, the liver benefiting nourishes blood; Make with Radix Angelicae Sinensis, can enrich blood invigorate blood circulation, promoting tissue regeneration by removing blood stasis, make blood fortune unobstructed.More than all medicines share, reinforcing and reducing are also executed, the merit that row stagnates and to promote blood circulation is played in treating both the principal and the secondary aspects of a disease at the same time altogether.
Active component in the lipid-lowering composition of the present invention can be the powder that above-mentioned Chinese crude drug is made through physical pulverization, also can be water extract or its concentrated solution of above-mentioned 5 flavor Chinese crude drugs, or ethanol extract, can also be that the water extract or the ethanol extract of part medicinal powder and other parts medical material formed.The water extract that is preferably above-mentioned Chinese crude drug is as active component; More preferably the water extract of Oriental Waterplantain Rhizome and other Chinese crude drugs is formed.
The preparation technology of active component is as follows in the lipid-lowering composition of the present invention: Rhizoma Alismatis powder is broken into powder, and standby; Radix Puerariae, Fructus Crataegi, the Radix Polygoni Multiflori, Radix Angelicae Sinensis four Chinese medicine material are decocted with water 2-3 time together, each 1-1.5 hour, merge decocting liquid, filter, filtrate concentrates, and adds ethanol and makes and contain the alcohol amount and reach 70%, leaves standstill, get supernatant and reclaim ethanol, concentrate and obtain clear paste, qinghuo reagent adds Rhizoma Alismatis powder, mixed pelletization, drying, promptly.
Active component preferred for preparation technology is as follows in the lipid-lowering composition of the present invention: Rhizoma Alismatis powder is broken into powder, Radix Puerariae, Radix Angelicae Sinensis, the Radix Polygoni Multiflori and Fructus Crataegi four flavors are decocted with water each 1.5 hours three times, collecting decoction filters, and filtrate is concentrated into relative density 1.05 (60 ℃), add ethanol and make and contain alcohol amount and reach 70%, stir evenly, leave standstill, get supernatant and reclaim ethanol, being concentrated into relative density is the clear paste of 1.25-1.30 (80 ℃), and qinghuo reagent adds Rhizoma Alismatis fine powder, mixed pelletization, drying, promptly.
The active component of lipid-lowering composition of the present invention can be prepared into various pharmaceutically acceptable dosage forms with pharmaceutically acceptable carrier, the preferred oral form of administration, as solid dosage forms tablet, granule, capsule etc., liquid preparation such as oral liquid, decoction, medicated wine, mixture etc.The preferred particulates agent.
Lipid-lowering composition of the present invention has dampness removing and reduces phlegm, the function of nourishing the liver and kidney.Be mainly used in clinically because of certain this disease, aging and hyperlipemia that functional disorder caused (the expectorant stasis of blood hinders the deficiency of the liver and kindey card of holding concurrently that stagnates).Pharmacodynamic study mainly is the foundation by relevant hyperlipemia animal model, observes its blood lipid regulation and the atherosis effect of prevention of arterial from zooperal angle.It is to the effect that experimental mice hyperlipemia has remarkable reduction TG, TC level, improves HDL-C content, and within the specific limits, the blood lipid regulation effect of lipid-lowering composition 1.6-4.8g/kg increases with the increase of dosage; In the experimental rat hyperlipemia model, lipid-lowering composition can significantly reduce the TC level, and the 3.24g/kg lipid-lowering composition also has significant reduction effect to rat TG content; Lipid-lowering composition also has preventive effect preferably to the pigeon experimental atherosclerosis, and serum lipids is also had certain reduction effect; To experimental rabbit hyperlipemia symptom model, lipid-lowering composition not only raises to effective control blood lipid level when the prevention administration, improves HDL-C content.When the treatment administration, hyperlipemia is also demonstrated the good curing effect, the most remarkable with the effect of 1.68-5.04g/kg dosage group.
Concrete embodiment
Embodiment 1
Take by weighing following raw materials in weight: Radix Puerariae 1667g, Fructus Crataegi (parched) 1667g, Rhizoma Alismatis 750g, Radix Polygoni Multiflori Preparata 667g, Radix Angelicae Sinensis 417g, standby;
Rhizoma Alismatis powder is broken into powder, Radix Puerariae, Radix Angelicae Sinensis, the Radix Polygoni Multiflori and Fructus Crataegi four flavors are decocted with water each 1.5 hours three times, collecting decoction filters, and filtrate is concentrated into relative density 1.05 (60 ℃), adding ethanol makes and contains alcohol amount and reach 70%, stir evenly, leave standstill, get supernatant and reclaim ethanol, being concentrated into relative density is the clear paste of 1.25-1.30 (80 ℃), qinghuo reagent adds the Rhizoma Alismatis fine powder, mixing, promptly.
Embodiment 2
Take by weighing the Chinese crude drug of following consumption: Radix Puerariae 3500g, Fructus Crataegi (parched) 3500g, Rhizoma Alismatis 1000g, Radix Polygoni Multiflori Preparata 1500g, Radix Angelicae Sinensis 500g, standby;
Above-mentioned Chinese crude drug is decocted with water twice, and each 1.5 hours, collecting decoction was condensed into thick paste, promptly.
Embodiment 3
Take by weighing the Chinese crude drug of following consumption: Radix Puerariae 3500g, Fructus Crataegi (parched) 2500g, Rhizoma Alismatis 1500g, Radix Polygoni Multiflori Preparata 1500g, Radix Angelicae Sinensis 1000g, standby;
With above-mentioned Chinese crude drug difference drying and grinding, cross 100 mesh sieves, mix homogeneously.
Embodiment 4
Take by weighing the Chinese crude drug of following consumption: Radix Puerariae 3200g, Fructus Crataegi (parched) 3300g, Rhizoma Alismatis 1500g, Radix Polygoni Multiflori Preparata 1200g, Radix Angelicae Sinensis 800g, standby;
With 70% alcohol reflux 4-8 hour, decompression recycling ethanol obtained ethanol extraction with above-mentioned medical material.
Embodiment 5
Take by weighing the Chinese crude drug of following consumption: Radix Puerariae 3100g, Fructus Crataegi (parched) 3400g, Rhizoma Alismatis 1500g, Radix Polygoni Multiflori Preparata 1200g, Radix Angelicae Sinensis 800g, standby;
Preparation process with embodiment 1.
Embodiment 6
Take by weighing the Chinese crude drug of following consumption: Radix Puerariae 3300g, Fructus Crataegi (parched) 3400g, Rhizoma Alismatis 1500g, Radix Polygoni Multiflori Preparata 1300g, Radix Angelicae Sinensis 500g, standby;
Preparation is with the step of embodiment 2.
Test example 1
Material and medicine
1 animal: Kunming mouse and Wistar rat, provide by Anhui Prov. Medical Science Inst. Animal Experimental Study chamber, possess real moving No. 01 quality certification of accurate word of Anhui doctor that Anhui Province management of laboratory animal committee authorizes.Pigeon and table purplish blue rabbit, epidemic prevention station animal housing in Anhui Province's provides.
2 medicines: the lipid-lowering composition active component is provided by Nanfang Pharmaceutical Factory, lot number: 921012.During use content is made into the medicinal liquid of variable concentrations with distilled water.Herb Gynostemmae Pentaphylli total glycosides is beach, a Shenzhen pharmaceutical Co. Ltd product, lot number: 920203.Fenofibrate (lipanthyl) is the big pharmaceutical factory of the French Buddhist nun of a section product.
3 reagent: ADP is a Sigma company product, and TG, TCH, LDL-C and HDL-c test kit are eastern bowl biological engineering reagent instrument plant product.
4 instruments: 72 type spectrophotometers, BS631 type platelet aggregation instrument, dual conductance type self-balancing recorder, blood viscometer (Shanghai first medical university's product).
Method and result
One, the lipid-lowering composition active component is got 100 of male mice in kunming to the influence of hyperlipemia mice model blood fat, be divided into 5 groups at random, be respectively normal control group, model group, model+1.60g/kg lipid-lowering composition group, model+4.80g/kg lipid-lowering composition group and 23.4mg/kg Herb Gynostemmae Pentaphylli total glycosides group.Each moulding group mice is irritated stomach respectively and gives lipomul (10% cholesterol, 20% Adeps Sus domestica, 20% sodium cholate and 1% methylthiouracil), only irritates stomach by 0.5ml/, once a day, and continuous irrigation stomach 14 days.The modeling type while, continuous irrigation stomach different pharmaceutical, the normal control group waits the capacity normal saline, successive administration 14 days.After the last administration finished, with each group mice fasting 12 hours, then, the rathole socket of the eye was got blood from childhood, and separation of serum by the requirement of test kit operation sequence, is measured respectively and respectively organized mice serum TG, TCH and HDL-ch content.The results are shown in Table 1.
Table 1 lipid-lowering composition to the influence of mice hyperlipemia model blood lipid level (X ± SD, n=20)
Group dosage TG TCH HDL-ch
(g/kg) (mmol/L) (mmol/L) (mmol/L)
Normal group 0.7 ± 0.13 3.23 ± 1.00 1.52 ± 0.15
Model group 2.14 ± 0.78 △ △ 5.34 ± 0.99 △ △ 1.44 ± 0.33
Lipid-lowering composition 1.60 1.26 ± 0.75
*5.22 ± 1.12 1.68 ± 0.48
Lipid-lowering composition 4.80 0.80 ± 0.31 4.27 ± 1.01
*2.13 ± 0.60
*
Jiaogulanoside 0.0234 1.35 ± 0.43
*4.76 ± 0.81 1.52 ± 0.27
Compare with normal group: △ △ P＜0.01
Compare with model group: * P＜0.05, * * P＜0.01
Table 1 result shows: compare with normal group, the TG of model group and TCH level all have significance to raise, and prove mice hyperlipemia model moulding success.1.60g/kg lipid-lowering composition can significantly reduce the serum TG level, but not obvious to TCH and HDL-ch effect.4.80g/kg lipid-lowering composition all has remarkable reduction to serum TG and TCH level, and HDL-ch content is increased significantly.Herb Gynostemmae Pentaphylli total glycosides has significant reduction to TG level in the mice serum.
Two, lipid-lowering composition is to the influence of experimental hyperlipemia in rats model blood fat
80 of extracting male Wistar rats are divided into 4 groups at random, are respectively model group, model+1.08g/kg lipid-lowering composition group, model+3.24g/kg lipid-lowering composition group and 16.2mg/kg Herb Gynostemmae Pentaphylli total glycosides group.Each moulding group rat is irritated stomach respectively and gives lipomul (10% cholesterol, 20% Adeps Sus domestica, 2% sodium cholate and 1% methylthiouracil), and press the 1.0ml/100g body weight and irritate stomach, once a day, continuous irrigation stomach 14 days.The modeling type while, continuous irrigation stomach different pharmaceutical, the normal control group waits the capacity normal saline, successive administration 14 days.After the last administration finishes, with each group rat fasting 12 hours, then, get blood from rat carotid artery, separation of serum by the requirement of test kit operation sequence, is measured respectively and is respectively organized rat blood serum TG, TCH and HDL-ch content.The results are shown in Table 2.
Table 2 lipid-lowering composition to the influence of hyperlipemia model of rats blood lipid level (X ± SD, n=20)
Dosage TG TCH HDL-ch
(mmol/L) (mmol/L) (mmol/L) for group (g/kg)
Model group 1.13 ± 0.33 △ △ 5.25 ± 1.59 1.49 ± 0.37
Lipid-lowering composition 1.08 0.97 ± 0.13 3.70 ± 1.13
*1.36 ± 0.19
Lipid-lowering composition 3.24 0.89 ± 0.19
*3.87 ± 0.91
*1.47 ± 0.29
Jiaogulanoside 0.0162 1.12 ± 0.27 4.09 ± 0.76
*1.10 ± 0.33
Compare with model group:
*P＜0.05
Table 2 result shows: the 1.08/kg lipid-lowering composition has the effect of remarkable reduction Serum TC H content, though TG is had certain reduction effect, significant difference is not arranged.3.24g/kg lipid-lowering composition all has remarkable reduction effect to serum TG and TCH content.Herb Gynostemmae Pentaphylli total glycosides has significant reduction to TCH level in the rat blood serum.But each administration group of lipid-lowering composition and Herb Gynostemmae Pentaphylli total glycosides group all do not have remarkable influence to HDL-ch content.
Three, lipid-lowering composition is got 40 of male hybrid pigeons to the influence of pigeon experimental atherosclerosis model blood fat, body weight is divided into 4 groups at random, is respectively model group, model+1.08g/kg lipid-lowering composition group, model+3.24g/kg lipid-lowering composition group and 16.2mg/kg Herb Gynostemmae Pentaphylli total glycosides group.Each moulding group pigeon is irritated stomach respectively and gives hypercholesterolemia lipomul (Adeps Sus domestica/cholesterol=20/1), only irritates stomach by 3.0ml/, once a day, and 8 weeks of continuous irrigation stomach.The modeling type while, continuous irrigation stomach different pharmaceutical, the normal control group waits the capacity normal saline, 8 weeks of successive administration.After the last administration finishes, with each group pigeon fasting 12 hours, then, put to death animal, get blood from carotid artery, separation of serum by the requirement of test kit operation sequence, is measured serum TG, TCH and HDL-ch content respectively.Separate pigeon heart, aorta and left and right sides brachiocephalic artery simultaneously and do the pathology inspection, the results are shown in Table 3.
Table 3 lipid-lowering composition to the influence of atherosclerosis pigeon blood lipid level (X ± SD, n=20)
Dosage TG TCH HDL-ch
(mmol/L) (mmol/L) (mmol/L) for group (g/kg)
Model group 2.33 ± 0.24 25.0 ± 0.79 6.18 ± 0.56
Lipid-lowering composition 1.08 1.96 ± 0.13
*23.7 ± 1.05
*6.02 ± 1.24
Lipid-lowering composition 3.24 2.10 ± 0.17
*23.0 ± 1.67
*5.77 ± 0.45
Jiaogulanoside 0.0162 2.21 ± 0.36 23.8 ± 0.84
*4.05 ± 0.85
*
Compare with model group: * P＜0.05, * * P＜0.01
Table 3 result shows: 1.08g/kg and 3.24g/kg dosage lipid-lowering composition all have significant reduction effect .HDL-ch content not have obvious influence to pigeon serum TG and TCH content.Herb Gynostemmae Pentaphylli total glycosides matched group serum TC H has remarkable reduction, but this treated animal serum hdl-ch content significantly reduces, and mechanism is not clear.
The prompting of aorta pathology check result: moulding group inner membrance has obvious yellow speckle to form the inner membrance partial thickening.Test under microscope is found that endarterium is general and is seen foam cell, atherosclerosis initial stage pathological changes occurs.Check that substantially arterial elasticity is poor.Each group of all the other administrations is not seen atherosclerotic lesion.
Four, lipid-lowering composition is to the influence of rabbit experiment hyperlipemia
Get 80 of male table purplish blue hybrid healthy rabbits, body weight 1.5-2.5kg.Before the experiment, the rabbit normal diet was fed 7 days, oneself gets blood by rabbit ear edge vein immediately, measures its TC, TG, LDL-ch and HDL-ch content respectively, and extrapolates VLDL-ch and TC/HDL-ch ratio.According to rabbit blood lipid level and body weight, rabbit is divided into 10 groups at random, 10 every group.The 1st group is the normal control group, gives the rabbit solid feed all the time.Other each group is used high lipid food (containing cholesterol 0.5%, Adeps Sus domestica 5%, rabbit solid feed 94.5%) instead.3-5 organizes when using high lipid food instead, mixes the lipid-lowering composition of raising large, medium and small three dosage respectively, once a day, and shared 4 weeks.6-8 is organized in the 5th week of using high lipid food instead and begins to mix the lipid-lowering composition of raising large, medium and small three dosage, and mix synchronously for the 10th group and raise positive control drug fenofibrate 30mg/kg, once a day, shared 4 weeks.Mix synchronously with 3-5 group for the 9th group and raise positive control drug fenofibrate 30mg/kg, once a day, 3-5 group and the 9th group are 4 weeks of medication, and drug withdrawal then continues to observe for 4 weeks.The 2nd group continues to mix to raise and gives high lipid food as model group with hyperlipemia.
The 2nd, 4,6,8 weekends of changing high lipid food, fasting was got blood from ear after 12 hours, measured TG, TC, LDL-C, HDL-C respectively and extrapolated VLDL-C and TC/HDL-C ratio.The results are shown in Table 4.
Table 4.1 lipid-lowering composition to the influence of rabbit anteserum TG content (X ± SD, n=8)
After the administration (mmol/L)
2W 4W 6W 8W before the group administration
I 0.73±0.29 0.76±0.42 0.73±0.42 0.60±0.26 0.59±0.32
II 0.60±0.26 1.77±0.59 2.30±0.94 3.02±1.07 3.76±1.22
III 0.58±0.26 1.74±0.66 1.75±0.57 2.20±0.90 3.08±1.12
IV 0.76±0.27 1.41±0.41 1.36±0.51
*?2.13±0.81 3.10±1.02
V 0.76±0.35 1.36±0.42 1.20±0.50
*?1.76±0.66
*?2.80±0.96
VI 0.72±0.27 2.03±0.78 2.53±0.88 2.67±0.88 2.95±0.92
VII 0.58±0.26 1.75±0.56 2.20±0.63 2.56±0.67 2.62±0.69
*
VIII 0.52±0.24 1.90±0.76 2.54±0.78 2.48±0.76 2.60±0.57
*
IX 0.70±0.25 1.28±0.58 1.34±0.41
*?2.11±0.59
*?2.96±0.89
X 0.74±0.30 1.80±0.59 2.28±0.43 2.60±0.74 2.68±0.57
*
VSII group: * P＜0.05
By table 4.1 as seen, give the clothes lipid-lowering composition simultaneously in the hyperlipemia moulding, around the 1.68 and 5.04g/kg (IV, V) dosage group show and control the effect (P＜0.05) that TG content raises preferably.0.56g/kg (III) also show certain inhibition trend.Each dosage group also presents certain drug action after the drug withdrawal.Wherein to act on the effect of positive control fenofibrate (IX) group close for 5.04g/kg (IV) group.Each group effect of administration shows around after the hyperlipemia moulding, and after the administration all around, lipid-lowering composition 1.68 and 5.04g/kg group (VI, VIII) all show the effect of better reduction TG content, and significant difference (P＞0.05) is arranged.
Table 4.2 lipid-lowering composition to the influence of rabbit anteserum TC content (X ± SD, n=8)
After the administration (mmol/L)
2W 4W 6W 8W before the group administration
I 1.83±0.54 1.72±0.95 1.78±0.81 1.95±0.62 1.89±0.67
II 1.73±0.74 9.55±2.55 15.6±2.83 18.2±4.41 17.8±4.03
III 2.23±0.61 8.07±2.23 12.2±3.72 15.2±3.14 18.0±4.34
IV 2.06±0.53 6.62±2.07 12.5±2.20
*?15.5±4.30 16.1±3.81
V 1.85±0.57 6.18±2.41 10.9±2.40
*?13.6±4.46
*?13.7±3.60
*
VI 2.09±0.63 7.68±3.04 16.4±3.40 16.6±3.64 14.7±3.68
VII 1.77±0.49 8.74±2.47 15.7±2.86 14.3±3.40
*?13.6±3.32
*
VIII 1.93±0.61 10.2±3.41 15.8±2.82 13.4±3.86
*?12.9±3.98
*
IX 1.85±0.66 6.94±2.03 12.0±3.32
*?13.7±3.77
*?14.9±3.00
XX 2.17±0.72 9.49±3.34 16.2±4.52 13.8±3.68
*?12.7±3.77
*
VS II group: * P＜0.05
By table 4.2 as seen, give the clothes lipid-lowering composition simultaneously in the hyperlipemia moulding, back 1.68 and 5.04g/kg (IV, V) dosage group show the effect (P＞0.05) that remarkable control TC content raises all around.In, heavy dose of group still shows certain control TC rising effect in drug withdrawal during 2 to 4 weeks, with 5.04g/kg effect remarkable (P, 0.05).0.56g/kg the effect trend that lipid-lowering composition (III) also has certain inhibition TC content to raise.The effect of positive control fenofibrate has heavy dose of lipid-lowering composition effect close.Playing each group effect of administration around after the moulding shows: lipid-lowering composition 1.68 and 5.04g/kg (VII, VIII) participant 0mg/kg fenofibrate group all has the effect of better reduction TC content, compares there was no significant difference between group.
Table 4.3 lipid-lowering composition to the influence of rabbit anteserum LDL-C content (X ± SD, n=8)
After the administration (mmol/L)
2W 4W 6W 8W before the group administration
I 0.80±0.23 0.73±0.34 0.78±0.31 0.84±0.31 0.83±0.26
II 0.75±0.33 6.95±1.86 11.8±2.74 13.7±4.35 13.4±3.19
III 0.99±0.25 5.62±1.53 8.96±2.34
* 11.5±3.38 13.7±4.28
IV 0.87±0.23 4.54±1.42
**?9.06±2.14
* 11.4±3.02 12.1±3.38
V 0.80±0.23 4.09±1.24
**?7.68±1.68
**?9.89±2.59
*?9.99±2.32
*
VI 0.92±0.22 5.32±1.81 12.3±3.40 12.5±2.95 10.9±2.87
VII 0.78±0.25 6.27±1.85 11.8±2.41 10.5±2.77 9.81±2.88
*
VIII?0.80±0.25 7.38±2.23 11.8±2.63 9.68±2.69
*?9.13±2.68
*
IX 0.75±0.26 4.60±1.55
**?8.51±2.19
* 9.88±2.69
*?10.8±2.62
X 1.04±0.35 6.85±2.07 12.1±3.40 9.94±2.81
* 8.93±2.84
**
VS II group: * P＜0.05, * * P＜0.01
By table 4.3 as seen, give lipid-lowering composition simultaneously in the hyperlipemia moulding, in, heavy dose of group (IV, V) all shows the effect of certain inhibition LDL-C content, (P＜0.01=acts on after the drug withdrawal LDL-c and still can keep in a period of time wherein with 1.68g/kg (IV) and 5.04g/kg (V) effect statistical significance to be arranged all extremely significantly.This effect is good like acting as than 30mg/kg fenofibrate group, but does not see significant difference (P＞0.05).Playing each group effect of administration around after the moulding shows; Each dosage group of lipid-lowering composition (VI, VII, VIII) all has certain reduction LDL-C effect, and remarkable with 1.68g/kg and 5.04g/kg effect, the P value has the effect that extremely significantly reduces LDL-C content less than around 0.05/30mg/kg fenofibrate group (X) administration.
Table 4.4 lipid-lowering composition to the influence of rabbit anteserum VLDL-C content (X ± SD, n=8)
After the administration (mmol/L)
2W 4W 6W 8W before the group administration
I 0.20±0.06 0.18±0.08 0.19±0.08 0.21±0.08 0.21±0.06
II 0.19±0.08 1.73±0.47 2.94±0.69 3.43±1.09 3.34±0.80
III 0.25±0.06 1.41±0.38 2.24±0.58 2.85±0.85 3.42±1.07
IV 0.22±0.06 1.14±0.36 2.27±0.54 2.88±0.76 3.02±0.85
V 0.20±0.10 1.02±0.31
**?1.92±0.42
**?2.47±0.65
**?2.50±0.58
VI 0.23±0.06 1.33±0.45 3.08±0.85 3.13±0.74 2.72±0.72
VII 0.20±0.06 1.57±0.46 2.95±0.60 2.63±0.69 2.45±0.72
VIII 0.20±0.08 1.85±0.56 2.94±0.66 2.42±0.67 2.28±0.67
IX 0.19±0.06 1.15±0.39 2.31±0.55
**?2.47±0.67 2.71±0.66
X 0.26±0.09 1.71±0.52 3.02±0.85 2.49±0.70 2.23±0.71
VSII group: * P＜0.05, * * P＜0.01
Table 4.4 shows: lipid-lowering composition 5.04g/kg group (V) has remarkable reduction VIDL-C content effect (P＜0.01), compares with 30mg/kg fenofibrate group (IX) and does not see significant difference.Table 4.5 lipid-lowering composition to the influence of rabbit anteserum HDL-C content (X ± SD, n=8)
After the administration (mmol/L)
2W 4W 6W 8W before the group administration
I 0.83±0.21 0.81±0.30 0.77±0.25 0.90±0.38 0.85±0.22
II 0.79±0.35 0.89±0.24 0.90±0.26 1.03±0.40 1.10±0.28
III 0.98±0.23 1.04±0.28 1.04±0.23 0.89±0.34 0.90±0.35
IV 0.97±0.27 0.95±0.29 1.17±0.35 1.09±0.27 1.00±0.32
V 0.85±0.34 1.07±0.23 1.33±0.29
* 1.25±0.25 1.21±0.24
VI 0.95±0.17 1.04±0.30 1.01±0.35 0.96±0.24 1.13±0.31
VII 0.79±0.28 0.90±0.28 0.96±0.27 1.18±0.29 1.34±0.46
VIII 0.93±0.28 0.97±0.26 1.10±0.30 1.30±0.35 1.49±0.42
*
IX 0.91±0.28 1.17±0.44 1.36±0.32
* 1.34±0.36 1.37±0.39
X 0.87±0.30 0.92±0.23 1.08±0.31 1.36±0.41 1.54±0.52
*
VSII group: * P＜0.05, * * P＜0.01
Table 4.5 shows: the effect (P＜0.01) of HDL-C content in the remarkable rising serum is all arranged around after 5.04g/kg lipid-lowering composition group (V, the VIII) administration.0.56mg/kg and the effect of 1.68g/kg group is not remarkable, but have certain effect trend.The effect of remarkable rising HDL-C content is arranged after positive control drug fenofibrate group (IX, the X) administration, compare there was no significant difference with lipid-lowering composition (V, VIII) group.
Table 4.6 lipid-lowering composition to the influence of rabbit anteserum TC/HDL-CX ratio (X ± SD, n=8)
After the administration (mmol/L)
2W 4W 6W 8W before the group administration
Not
I 2.21±0.61 2.12±0.98 2.33±0.94 2.17±0.69 2.22±0.68
II 2.18±0.95 10.8±2.90 17.4±4.04 17.6±5.59 16.2±3.86
III 2.26±0.57 7.76±2.11 11.8±3.07
**?17.1±5.06 20.1±6.28
IV 2.13±0.57 7.01±2.19
* 10.7±2.52
**?14.2±3.72 16.0±4.52
V 2.17±0.76 5.78±1.75
**?8.22±1.80
**?10.9±2.86
**?11.3±2.63
*
VI 2.21±0.53 7.42±2.53 16.3±4.49 17.3±4.09 13.0±3.44
VII 2.44±0.70 9.71±2.86 16.4±3.34 12.1±3.20
* 10.2±2.99
*
VIII 2.08±0.64 10.5±3.18 14.4±3.22 10.3±2.87
** 8.67±2.55
**
IX 2.03±0.68 5.83±1.96
* 8.81±2.26
**?10.2±2.77
** 10.9±2.63
*
X 2.49±0.84 10.3±3.12 15.0±4.21 10.1±2.86
** 8.24±2.62
*
VSII group: * P＜0.05, * * P＜0.01
Table 4.6 shows: give the clothes lipid-lowering composition simultaneously in the hyperlipemia moulding, large, medium and small dosage group (III, IV, V) all can reduce TC/HDL-C ratio, and significant dose-effect relationship is arranged.The effect of V group is similar to fenofibrate (IX) effect.But there was no significant difference.V, IX still can keep after group 4 weeks of drug withdrawal.4 week administration effects show after the hyperlipemia moulding: after the administration 1.68 and 5.04g/kg lipid-lowering composition group (VII VIII) effect of remarkable reduction TC/HDL-C ratio is all arranged, act on and be similar to fenofibrate group (X).
Lipid metabolic disorder, serum total cholesterol (TC), triglyceride (TG), low density lipoprotein, LDL (LDL) and very low density lipoprotein (VLDL) (VLDL) raise, and high density lipoprotein (HDL) reduction, be the major reason that forms atherosclerosis and cause a series of cardiovascular and cerebrovascular disease.Blood fat raises, and especially cholesterol concentration increases, and with generation, the development of cerebral ischemia substantial connection is arranged.
Many index is selected in this experiment for use, comprehensive observing the blood lipid regulation of lipid-lowering composition, the atherosis generation of prevention of arterial and improve hemorheological effect.Experimental result shows that lipid-lowering composition possesses the effect that reduces the big mice of hyperlipemia model and TG, TC level preferably, improves HDL-C content, and within the specific limits, the blood lipid regulation effect of lipid-lowering composition 1.6-4.8g/kg increases with the increase of dosage; Lipid-lowering composition also has preventive effect preferably to the pigeon experimental atherosclerosis, and serum lipids is also had certain reduction effect; To experimental rabbit hyperlipemia model, lipid-lowering composition not only can effectively be controlled blood lipid level and raise when the prevention administration, improve HDL-c content.When the treatment administration, hyperlipemia is put down the good curing effect that also demonstrates.
Claims (6)
1. Chinese traditional medicines depressing lipid compositions, it is made up of active component and/or pharmaceutically receivable carrier, and wherein active component is made by following raw materials by weight percent: Radix Puerariae 25-35%, Fructus Crataegi 25-35%, Rhizoma Alismatis 10-20%, Radix Polygoni Multiflori 10-15% and Radix Angelicae Sinensis 5-10%.
2. according to the described Chinese traditional medicines depressing lipid compositions of claim 1, wherein prepare the active component raw material consumption and be: Radix Puerariae 28-33%, Fructus Crataegi 29-34%, Rhizoma Alismatis 10-15%, Radix Polygoni Multiflori 10-1 3% and Radix Angelicae Sinensis 6-9%.
3. according to the described Chinese traditional medicines depressing lipid compositions of claim 2, wherein prepare the active component raw material consumption and be: Radix Puerariae 32%, Fructus Crataegi 32%, Rhizoma Alismatis 15%, Radix Polygoni Multiflori 13% and Radix Angelicae Sinensis 8%.
4. according to any one described lipid-lowering composition among the claim 1-3, wherein Fructus Crataegi is a Fructus Crataegi (parched), and Radix Polygoni Multiflori is a Radix Polygoni Multiflori Preparata.
5. any one described preparation of drug combination method among the claim 1-4, it comprises the following steps: Rhizoma Alismatis powder is broken into powder, and is standby; Radix Puerariae, Fructus Crataegi, the Radix Polygoni Multiflori, Radix Angelicae Sinensis four Chinese medicine material are decocted with water 2-3 time together, each 1-1.5 hour, merge decocting liquid, filter, filtrate concentrates, and adds ethanol and makes and contain the alcohol amount and reach 70%, leaves standstill, get supernatant and reclaim ethanol, concentrate and obtain clear paste, qinghuo reagent adds Rhizoma Alismatis powder, mixed pelletization, drying, promptly.
6. according to the described preparation method of claim 5, it comprises the following steps: Rhizoma Alismatis powder is broken into powder, and Radix Puerariae, Radix Angelicae Sinensis, the Radix Polygoni Multiflori and Fructus Crataegi four flavors are decocted with water three times, each 1.5 hours, collecting decoction filtered, filtrate is concentrated into 60 ℃, and to survey relative densities be 1.05, adds ethanol and make and contain the alcohol amount and reach 70%, stirs evenly, leave standstill, get supernatant and reclaim ethanol, being concentrated into 80 ℃ of survey relative densities is the clear paste of 1.25-1.30, qinghuo reagent adds the Rhizoma Alismatis fine powder, mixed pelletization, drying, promptly.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03108971 CN1283288C (en) | 2003-04-15 | 2003-04-15 | Composition of medicine for lowering fat, and its prepn. method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03108971 CN1283288C (en) | 2003-04-15 | 2003-04-15 | Composition of medicine for lowering fat, and its prepn. method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1537544A true CN1537544A (en) | 2004-10-20 |
| CN1283288C CN1283288C (en) | 2006-11-08 |
Family
ID=34319168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03108971 Expired - Lifetime CN1283288C (en) | 2003-04-15 | 2003-04-15 | Composition of medicine for lowering fat, and its prepn. method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1283288C (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101850031A (en) * | 2010-04-23 | 2010-10-06 | 胡庆禧 | Pueraria isoflavone capsule |
| CN104435447A (en) * | 2014-12-16 | 2015-03-25 | 山东京御堂国药有限公司 | Lipid-lowering sustained-release preparation prepared from kudzuvine roots and hawthorn fruits and preparation method thereof |
| CN104473957A (en) * | 2014-12-16 | 2015-04-01 | 山东京御堂国药有限公司 | Traditional Chinese medicine monomer composition for reducing lipids and preparation of traditional Chinese medicine monomer composition |
| CN104474169A (en) * | 2014-12-16 | 2015-04-01 | 山东京御堂国药有限公司 | Radix puerariae-hawthorn lipid-reducing granules and preparation method thereof |
| CN104491239A (en) * | 2014-12-16 | 2015-04-08 | 山东京御堂国药有限公司 | Traditional Chinese medicine composition for reducing fat and preparation thereof |
| CN104510857A (en) * | 2014-12-16 | 2015-04-15 | 山东京御堂国药有限公司 | Traditional Chinese medicinal effective part composition for lowering lipid and preparations of traditional Chinese medicinal effective part composition |
| CN104623136A (en) * | 2015-01-12 | 2015-05-20 | 李元勋 | Traditional Chinese medicine health product for assisting blood-lipid reduction, namely angelica sinensis and astragalus membranaceus blood-lipid reducing granules and preparation method thereof |
| CN105249321A (en) * | 2015-09-01 | 2016-01-20 | 上海医药工业研究院 | Composition and preparation method and application thereof |
| CN105250671A (en) * | 2015-11-09 | 2016-01-20 | 谢桂斌 | Medicine for treating hyperlipoidemia |
-
2003
- 2003-04-15 CN CN 03108971 patent/CN1283288C/en not_active Expired - Lifetime
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101850031A (en) * | 2010-04-23 | 2010-10-06 | 胡庆禧 | Pueraria isoflavone capsule |
| CN101850031B (en) * | 2010-04-23 | 2012-06-27 | 胡庆禧 | Pueraria isoflavone capsule |
| CN104510857A (en) * | 2014-12-16 | 2015-04-15 | 山东京御堂国药有限公司 | Traditional Chinese medicinal effective part composition for lowering lipid and preparations of traditional Chinese medicinal effective part composition |
| CN104473957A (en) * | 2014-12-16 | 2015-04-01 | 山东京御堂国药有限公司 | Traditional Chinese medicine monomer composition for reducing lipids and preparation of traditional Chinese medicine monomer composition |
| CN104474169A (en) * | 2014-12-16 | 2015-04-01 | 山东京御堂国药有限公司 | Radix puerariae-hawthorn lipid-reducing granules and preparation method thereof |
| CN104491239A (en) * | 2014-12-16 | 2015-04-08 | 山东京御堂国药有限公司 | Traditional Chinese medicine composition for reducing fat and preparation thereof |
| CN104435447A (en) * | 2014-12-16 | 2015-03-25 | 山东京御堂国药有限公司 | Lipid-lowering sustained-release preparation prepared from kudzuvine roots and hawthorn fruits and preparation method thereof |
| CN104435447B (en) * | 2014-12-16 | 2016-01-20 | 山东京御堂国药有限公司 | A kind of Ge Shan blood fat reducing slow releasing preparation and preparation method thereof |
| CN104473957B (en) * | 2014-12-16 | 2016-02-03 | 山东京御堂国药有限公司 | A kind of Chinese medicine monomer compositions for blood fat reducing and preparation thereof |
| CN104491239B (en) * | 2014-12-16 | 2016-03-16 | 山东京御堂国药有限公司 | A kind of Chinese medicine composition for blood fat reducing and preparation thereof |
| CN104623136A (en) * | 2015-01-12 | 2015-05-20 | 李元勋 | Traditional Chinese medicine health product for assisting blood-lipid reduction, namely angelica sinensis and astragalus membranaceus blood-lipid reducing granules and preparation method thereof |
| CN104623136B (en) * | 2015-01-12 | 2018-08-28 | 李元勋 | A kind of auxiliary antilipemic Chinese herbal medicine health products Radix Angelicae Sinensis Radix Astragali blood-fat-lowering granule and preparation method thereof |
| CN105249321A (en) * | 2015-09-01 | 2016-01-20 | 上海医药工业研究院 | Composition and preparation method and application thereof |
| CN105250671A (en) * | 2015-11-09 | 2016-01-20 | 谢桂斌 | Medicine for treating hyperlipoidemia |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1283288C (en) | 2006-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1159047C (en) | Active components of Chinese-medicinal medicine with weight-losing and hypolipemic actions and its relative medicine | |
| CN1082904A (en) | Treat dermopathic pharmaceutical composition | |
| CN1903250A (en) | Method for extraction and separation of red rooted salvia | |
| CN1245202C (en) | Medicine for preventing and treating bone fracture and osteoporosis | |
| CN1879833A (en) | An wind-expelling ointment and method for preparing same | |
| CN1628786A (en) | Medicine for treating hyperlipemia | |
| CN1537544A (en) | Composition of medicine for lowering fat, and its prepn. method | |
| CN1840001A (en) | Method for preparing mixture with pubescent angelica root and loranthus | |
| CN115120692A (en) | Diglyceride composition for reducing blood fat and preparation method thereof | |
| CN1239183C (en) | A pharmaceutical composition made from Chinese traditional medicine and preparation method thereof | |
| CN1191082C (en) | Chinese medicinal composition for treating fatty liver and its preparation method | |
| CN1039286C (en) | Chinese proprietary medicine for anti old and feeble | |
| CN100344315C (en) | Medicinal composition for promoting bone fracture healing and its preparing method | |
| CN1562337A (en) | Chinese traditional medicine for treating insufficiency of kidney-yang and preparaton method | |
| CN1258372C (en) | Chinese medicinal composition for treating intestine irritable syndrome and its preparing method | |
| CN1212141C (en) | Application of atractylodes rhizome oil in preparing medicine for osteoporosis | |
| CN1548138A (en) | Chinese medicine composition for treating consumptive disease and its quality control method | |
| CN1194743C (en) | Chinese medicinal composition for treating atrophic arthritis, preparing method and quality controlling method thereof | |
| CN1651036A (en) | Angelica root mistletoe granules and its preparation method | |
| CN1202843C (en) | Drug rehabilitation oral liquid | |
| CN1257737C (en) | Traditional Chinese medicine composition for treating migraine and preparation method thereof | |
| CN1634463A (en) | Medicine for treating diabetes and production method thereof | |
| CN1197611C (en) | Medicine for curing choleithiasis and preparing method thereof | |
| CN1216614C (en) | Pharmaceutical composition for delaying chronic renal failure | |
| CN1336233A (en) | Hepatitis B treating medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Anhui Academy of Medical Sciences Document name: Notification of acceptance |
|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: SHANDONG LVYIN PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: ANHUI PROVINCE MEDICINE SCIENCE INSTITUTE; SANJIU PHARMACEUTICAL CO., LTD. Effective date: 20071123 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20071123 Address after: Linyi hi tech Industrial Development Zone, Shandong, China: 276017 Patentee after: SHANDONG LUYIN PHARMACEUTICAL Address before: No. 15, Yonghong Road, Hefei, Anhui: 230061 Co-patentee before: Sanjiu Medical & Pharmaceutical Co.,Ltd. Patentee before: Anhui Prov. Medical Science Research Inst. |
|
| ASS | Succession or assignment of patent right |
Owner name: SHANDONG JINGYUTANG TRADITIONAL CHINESE MEDICINE C Free format text: FORMER OWNER: SHANDONG LUYIN PHARMACEUTICAL CO., LTD. Effective date: 20131204 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 276017 LINYI, SHANDONG PROVINCE TO: 276015 LINYI, SHANDONG PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20131204 Address after: 276015 south section of industry road three, Ma Hu Town, hi tech Development Zone, Shandong, Linyi Patentee after: JINGYUTANG PHARMACEUTICAL CO.,LTD. Address before: 276017 hi tech Industrial Development Zone, Shandong, Linyi Patentee before: SHANDONG LUYIN PHARMACEUTICAL |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20220830 Address after: 276600 west side of the middle section of Gongye Third Road, high tech Zone, Linyi City, Shandong Province Patentee after: Shandong jingyutang Pharmaceutical Co.,Ltd. Address before: 276015 south section of Gongye 3rd road, machanghu Town, high tech Development Zone, Linyi City, Shandong Province Patentee before: JINGYUTANG PHARMACEUTICAL CO.,LTD. |
|
| CX01 | Expiry of patent term |
Granted publication date: 20061108 |
|
| CX01 | Expiry of patent term |